Navigation Links
DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
Date:12/20/2007

Strategic partnership with industry leader gives DRAXIMAGE strong

competitive position in nuclear medicine's largest market segment

MONTREAL, Dec. 20 /PRNewswire-FirstCall/ - DRAXIMAGE, the radiopharmaceutical division of DRAXIS Health Inc. (TSX: DAX) (NASDAQ: DRAX), has appointed GE Healthcare, an industry leader in nuclear medicine, as the exclusive distributor of DRAXIMAGE(R) Sestamibi in the United States. DRAXIMAGE(R) Sestamibi is a generic kit for the preparation of Technetium (Tc-99m) Sestamibi injection, a diagnostic cardiac imaging agent used in myocardial perfusion imaging (MPI) to evaluate blood flow to the heart. Cardiac imaging currently accounts for nearly half of the more than 20 million nuclear medicine procedures conducted in the United States.

DRAXIMAGE has granted GE Healthcare the exclusive right to market, distribute and sell its generic DRAXIMAGE(R) Sestamibi in the U.S. market and through its U.S. and Canadian radiopharmacy network once the primary innovator patent expires and marketing authorizations are received from the U.S. Food and Drug Administration (FDA) and Health Canada. Furthermore, GE Healthcare has agreed to purchase Technetium 99m Sestamibi injection exclusively from DRAXIMAGE. The initial term of the distribution agreement is for a minimum of three years following FDA approval of the DRAXIMAGE product.

An Abbreviated New Drug Application (ANDA) for DRAXIMAGE(R) Sestamibi was submitted by DRAXIMAGE to the FDA in February 2007 and this ANDA is currently under review. In addition, DRAXIMAGE recently announced the filing of DRAXIMAGE(R) Sestamibi with European and Canadian regulatory authorities seeking additional marketing authorizations.

"Working with GE Healthcare to bring this major product to the market is a significant opportunity for both partners," said Jean-Pierre Robert, President of DRAXIS Specialty Pharmaceuticals Inc., the operating subsidiary of DRAXIS Health. "Strong distribu
'/>"/>

SOURCE DRAXIS Health Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
2. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
3. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
4. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
5. Mediware Names Thomas K. Mann Chief Executive Officer
6. Cleveland-based Health Care Tech Company Within3 Names New CEO
7. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
8. Patient Safety Authority Board of Directors Names Infection Advisory Panel
9. Hooper Holmes Names Chris Behling President of Health & Wellness Division
10. MDMA Names New Director of Federal Affairs
11. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... First Choice Emergency Room opened ... The new facility is located 1501 FM 685, Pflugerville, Texas ... to be a part of First Choice Emergency Room’s second ... deliver high quality emergency medical care to the local community,” ... Emergency Room Pflugerville – FM 685. , To ...
(Date:8/29/2014)... What is bullying and why does it matter in ... harming, mistreatment by one or more people. It takes ... It is a form of abusive conduct very much ... bullying is a wide range of misconduct, but for us, ... short of the physical, just short of battery.” , “There ...
(Date:8/29/2014)... San Diego, CA (PRWEB) August 29, 2014 ... regarding all the latest information from the FDA on ... on August 26, that several sterile convenience surgical packs, by ... of sterility. , The reason for the recall is ... lead to loss of product sterility and infection. The affected ...
(Date:8/29/2014)... The Florida Chiropractic Association held its ... last week August 21-24 and Maryland and Virginia chiropractor ... , Dr. Greenstein presented at three different ... a standing room session; (2) A Panelist at the ... Leading the Way in Injury Prevention and Maximizing Human ...
(Date:8/29/2014)... Canadian Healthy Vending , the largest ... annual survey of its 200 operators from every region ... that appeal to Canadian consumer seeking refreshment at healthy ... top five selling healthy snacks and top five selling ... issue for consumers, employers, and families. Everyone wants to ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Pflugerville, Texas 2Health News:Bullying Expert Dr. Gary Namie discusses NCAA and Professional Sports with Sports Conflict Institute 2Health News:Bullying Expert Dr. Gary Namie discusses NCAA and Professional Sports with Sports Conflict Institute 3Health News:Sterile Convenience Surgical Packs by Customed, Inc. Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Sport and Spine Rehab’s CEO Presents at the Florida Chiropractic Association National Convention and Expo 2014 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 3
... percent of food products specifically targeted to babies and ... than 20 per centof calories coming from sugar, according ... Charlene Elliott. The study, funded by the ... sugar and sodium levels in 186 food products specifically ...
... the Gulf of Mexico, and they are concerned about its potential ... from a continuing survey conducted by the University of Minnesota. ... conducted by The Food Industry Center at the U of M. ... were aware of the spill and 85 percent say they are ...
... ... needs of athletes by offering all natural custom energy bars at elementendurance.com. , ... Chicago, IL (PRWEB) June 28, 2010 -- ... athletes to build their own all-natural, custom energy bars to their training and race needs. ...
... tooth-bleaching agent may improve the oral health of elderly ... of Georgia and Western University of Health Sciences. ... be difficult or impossible for patients with mental challenges ... medications cause xerostomia, or dry mouth, the lack of ...
... the Iacocca Foundation announce today the completion of the Phase ... as the submission of all safety reports to the U.S. ... monitoring boards. Plans for the Phase II clinical study, which ... a treatment for people with existing type 1 diabetes, are ...
... June 28, 2010 In the first ever published estimate ... with their minor children, a team led by a Wake ... cancer survivors are parenting young children, highlighting a group of ... in Cancer , a peer-reviewed journal of the American ...
Cached Medicine News:Health News:Toddler foods too sweet 2Health News:Toddler foods too sweet 3Health News:Element Endurance – Custom Energy Bars for Athletes 2Health News:Tray bleaching may improve oral health of elderly, special-needs patients 2Health News:Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial 2Health News:More than a million parents with minor children are cancer survivors 2
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Therapeutics to 2020 - Broadened Diagnostic ... Drive Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 ...
(Date:8/28/2014)... OAKS, Calif. , Aug. 28, 2014 ... submission of a Biologics License Application (BLA) to the ... approval for the treatment of high cholesterol. Evolocumab is ... convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces ... or "bad" cholesterol, from the blood. 1 ...
Breaking Medicine Technology:Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with curved 1 x 2 teeth. Serrated handle with polished finish....
Straight shafts, 1 x 2 teeth. Wide serrated handle with polished finish. Teeth: 0.3 mm. Most popular size or model....
Straight shafts with delicate 0.7 mm, 1 x 2 teeth. Serrated handle with polished finish....
Medicine Products: